Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Galapagos ( (GLPG) ) has shared an announcement.
On August 6, 2025, Galapagos NV announced that the U.S. FDA granted RMAT designation to its GLPG5101, a second-generation CAR-T product candidate, for treating relapsed/refractory mantle cell lymphoma. This designation, supported by promising clinical data from the ATALANTA-1 study, allows for accelerated development and closer collaboration with the FDA, potentially enhancing Galapagos’ position in the biotechnology industry and offering new treatment options for patients.
The most recent analyst rating on (GLPG) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
The overall stock score reflects significant financial challenges, particularly in cash flow and profitability, overshadowed by strong technical indicators suggesting positive market momentum. While the company has strategic plans to expand its pipeline and manufacturing, high restructuring costs and anticipated cash burn remain key concerns.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos is a biotechnology company operating in Europe, the U.S., and Asia, focused on transforming patient outcomes through innovative science. The company targets high unmet medical needs with a pipeline of best-in-class medicines, utilizing capabilities from lab to patient, including a decentralized cell therapy manufacturing platform.
Average Trading Volume: 364,176
Technical Sentiment Signal: Hold
Current Market Cap: $2.14B
Learn more about GLPG stock on TipRanks’ Stock Analysis page.